Advanced Search

Study Preview



Study Title and Description

Improvement effect of resistant maltodextrin in humans with metabolic syndrome by continuous administration.



Key Questions Addressed
1 Is this a fiber intervention study?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Improvement effect of resistant maltodextrin in humans with metabolic syndrome by continuous administration.
Author Hashizume C., Kishimoto Y., Kanahori S., Yamamoto T., Okuma K., Yamamoto K.
Country Matsutani Chemical Industry Co., Ltd., Hyogo, Japan.
Year 2012
Numbers Pubmed ID: 23419401

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Fiber Database
Arms
No arms have been defined in this extraction form.

Design Details
Question... Follow Up Answer Follow-up Answer
Year of Publication 2012
  • Comments Comments (
    0
    ) |
Country of Publication Japan
  • Comments Comments (
    0
    ) |
What was the study design? Randomized Controlled Trial (parallel)
  • Comments Comments (
    0
    ) |
Was the study blinded? double blind
  • Comments Comments (
    0
    ) |
Study diet type Isocaloric/Maintenance
  • Comments Comments (
    0
    ) |
Level of feeding control for dietary intervention Food partially provided
  • Comments Comments (
    0
    ) |
Sample size 30
  • Comments Comments (
    0
    ) |
Is there a run-in period? No
  • Comments Comments (
    0
    ) |
Is there a washout period? No
  • Comments Comments (
    0
    ) |
Did the administered fiber dose change over the course of the study? No
  • Comments Comments (
    0
    ) |
What is the age of the population (categorical)? Adults (20+ Years)
  • Comments Comments (
    0
    ) |
Study population, mean age in years 60.65
  • Comments Comments (
    0
    ) |
Study population, age range in years -
  • Comments Comments (
    0
    ) |
Study Population, mean BMI, kg/m2 ~27
  • Comments Comments (
    0
    ) |
Study population, BMI Range, kg/m2 -
  • Comments Comments (
    0
    ) |
Baseline health status Metabolic Syndrome
  • Comments Comments (
    0
    ) |
Gender (% male) ~67
  • Comments Comments (
    0
    ) |
Fiber 1-type Resistant Maltodextrin
  • Comments Comments (
    0
    ) |
Fiber 1-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 1-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 1- dose 1 (g) ~27
  • Comments Comments (
    0
    ) |
Fiber 1- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 1-Duration of intervention 12 weeks
  • Comments Comments (
    0
    ) |
Fiber 1-how was the fiber administered? Beverage
  • Comments Comments (
    0
    ) |
Fiber 2-type -
  • Comments Comments (
    0
    ) |
Fiber 2-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 2-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 2- dose 1 (g) -
  • Comments Comments (
    0
    ) |
Fiber 2- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 2-Duration of intervention -
  • Comments Comments (
    0
    ) |
Fiber 2-how was the fiber administered? -
  • Comments Comments (
    0
    ) |
Fiber 3-type -
  • Comments Comments (
    0
    ) |
Fiber 3-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 3-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 3- dose 1 (g) -
  • Comments Comments (
    0
    ) |
Fiber 3- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 3-Duration of intervention -
  • Comments Comments (
    0
    ) |
Fiber 3-how was the fiber administered? -
  • Comments Comments (
    0
    ) |
Fiber 4-type -
  • Comments Comments (
    0
    ) |
Fiber 4-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 4-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 4- dose 1 (g) -
  • Comments Comments (
    0
    ) |
Fiber 4- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 4-Duration of intervention -
  • Comments Comments (
    0
    ) |
Fiber 4-how was the fiber administered? -
  • Comments Comments (
    0
    ) |
Comparator 1- what was the comparator used in the intervention? Placebo tea drink
  • Comments Comments (
    0
    ) |
Comparator 1-dose 0
  • Comments Comments (
    0
    ) |
Comparator 1-duration of comparator intervention 12 weeks
  • Comments Comments (
    0
    ) |
Comparator 1-how was the comparator administered to participants? Beverage
  • Comments Comments (
    0
    ) |
Comparator 2- what was the comparator used in the intervention? -
  • Comments Comments (
    0
    ) |
Comparator 2-dose -
  • Comments Comments (
    0
    ) |
Comparator 2-duration of comparator intervention -
  • Comments Comments (
    0
    ) |
Comparator 2-how was the comparator administered to participants? -
  • Comments Comments (
    0
    ) |
Comparator 3- what was the comparator used in the intervention? -
  • Comments Comments (
    0
    ) |
Comparator 3-dose -
  • Comments Comments (
    0
    ) |
Comparator 3-duration of comparator intervention -
  • Comments Comments (
    0
    ) |
Comparator 3-how was the comparator administered to participants? -
  • Comments Comments (
    0
    ) |
Comparator 4- what was the comparator used in the intervention? -
  • Comments Comments (
    0
    ) |
Comparator 4-dose -
  • Comments Comments (
    0
    ) |
Comparator 4-duration of comparator intervention -
  • Comments Comments (
    0
    ) |
Comparator 4-how was the comparator administered to participants? -
  • Comments Comments (
    0
    ) |


Baseline Characteristics
No baseline characteristics have been defined for this extraction form.



Results & Comparisons

No Results found.
Adverse Events
Arm or Total Title Description Comments

Quality Dimensions
No quality dimensions were specified.

Quality Rating
No quality rating data was found.